| Pharmaceutical composition used in kit for treating cancer, e.g., breast cancer, melanoma, colorectal cancer, non-small cell lung cancer, comprises tyrosine kinase inhibitor and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor or antiprotozoal drugs optionally along with the excipients | |
| 2023-10-04 | |
| 专利权人 | MANKIND PHARMA LTD (MANK-Non-standard) |
| 申请日期 | 2023-10-04 |
| 专利号 | IN202311066521-A |
| 成果简介 | NOVELTY - Pharmaceutical composition comprises: tyrosine kinase inhibitor and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor or antiprotozoal drugs optionally along with one or more excipients. USE - Pharmaceutical composition used in kit for treating cancer (all claimed), e.g., breast cancer, melanoma, colorectal cancer, non-small cell lung cancer. Test details are described but no results given. ADVANTAGE - The pharmaceutical composition exhibits synergistic effect; improve bioavailability, and ease of administration. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: 1. a pharmaceutical combination for cancer, which comprises: dasatinib, simvastatin or quinacrine; and 2. a kit, which comprises: (a) composition comprising dasatinib and excipients; (b) composition comprising quinacrine or simvastatin and excipients; where composition of dasatinib, composition of quinacrine or simvastatin are administered either simultaneously, concurrently, alternately or sequentially. |
| IPC 分类号 | A61K-031/277 ; A61K-031/404 ; A61K-031/506 ; A61K-045/06 ; A61P-035/02 ; A61P-043/00 |
| 国家 | 印度 |
| 专业领域 | 医药卫生 |
| 语种 | 英语 |
| 成果类型 | 专利 |
| 文献类型 | 科技成果 |
| 条目标识符 | http://119.78.100.226:8889/handle/3KE4DYBR/20135 |
| 专题 | 中国科学院新疆生态与地理研究所 |
| 作者单位 | MANKIND PHARMA LTD (MANK-Non-standard) |
| 推荐引用方式 GB/T 7714 | KUMAR A,RAI S K,KUMAR R. Pharmaceutical composition used in kit for treating cancer, e.g., breast cancer, melanoma, colorectal cancer, non-small cell lung cancer, comprises tyrosine kinase inhibitor and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor or antiprotozoal drugs optionally along with the excipients. IN202311066521-A[P]. 2023. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论